Global Gynecomastia Procedures Market Size To Exceed USD 1900 Million by 2033 | CAGR Of 8.05% [Yahoo! Finance]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
to reach USD 1900 Million by 2033, according to a research report published by Spherical Insights & Consulting. Companies Covered: Cadila Pharmaceuticals Ltd, Biochem Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Micro Nova Pharmaceuticals Ltd, Kee Pharma Ltd, Sun Pharmaceuticals Industries Ltd, Zydus Cadila Healthcare Ltd, Allergan (AbbVie Inc.), Sientra, Inc., GC Aesthetics, POLYTECH Health & Aesthetics GmbH, Mentor Worldwide LLC (Johnson & Johnson), and other key companies. New York, United States, March 15, 2024 (GLOBE NEWSWIRE) -- The Global Gynecomastia Procedures Market Size is to Grow from USD 876 Million in 2023 to USD 1900 Million by 2033, at a Compound Annual Growth Rate (CAGR) of 8.05% during the projected period. Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/3845 Gynecomastia procedures are surgical procedures used to treat gynecomastia, a condition in which men develop excessive breast tissue. This could be due to hormon
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Indian drugmaker Lupin misses quarterly profit estimates as costs rise [Reuters]Reuters
- Global Migraine Drugs Market Report 2024, By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants), By Route of Administration (Oral, Injectable) and By End-User [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.Business Wire
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Nestlé signs India venture with pharma group Dr Reddy's [Yahoo! Finance]Yahoo! Finance
RDY
Earnings
- 1/31/24 - Beat
RDY
Sec Filings
- 5/3/24 - Form 6-K
- 4/30/24 - Form 6-K
- 4/25/24 - Form 6-K
- RDY's page on the SEC website